Literature DB >> 23598967

Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors.

Ta-Chiang Liu1, Nicholas Hamilton, William Hawkins, Feng Gao, Dengfeng Cao.   

Abstract

It is difficult to predict prognosis in patients with locoregional well-differentiated (WD) pancreatic neuroendocrine tumors (PanNET). We aimed to examine commonly used stratification systems [World Health organization (WHO) 2004 and 2010 classifications, American Joint Committee on Cancer (AJCC) and European Neuroendocrine Tumor Society (ENETS) staging, and the Hochwald grading system] for their power in predicting recurrence-free survival (RFS) in these patients. Seventy-five such patients (mean age 56 y, mean follow-up 79 mo) who underwent resection with sufficient tissue material and follow-up data were studied. RFS was correlated with variable clinicopathologic features and stratified with above-mentioned systems. Concordance index (CI) was then calculated. With the WHO 2004 classification, 16, 35, and 24 PanNETs were classified as benign behavior, uncertain behavior, and WD endocrine carcinoma, respectively. By the WHO 2010 classification, 26, 41, and 8 tumors were grade 1, 2, and 3, respectively. Using the Hochwald system, 47 were low grade, and 28 were intermediate grade. The AJCC staging information was complete for 62 patients (13 had the lymph node status Nx) and included: stages IA (19/62), IB (10/62), IIA (10/62), and IIB (23/62). The ENETS staging information was stages I (16/62), IIa (8/62), IIb (14/62), IIIa (0/62), and IIIb (24/62). The average Ki-67 proliferation index (PI) was 8.1%. Factors that predicted RFS included tumor size, nodal metastasis, vascular invasion, perineural invasion, necrosis, mitosis, and Ki-67 PI (all P<0.01). The CI for each system was: 0.6361 for WHO 2004, 0.6735 for WHO 2010, 0.6495 for AJCC staging, 0.6642 for ENETS staging, and 0.6851 for the Hochwald grading system. When these systems were analyzed in conjunction with various additional important pathologic features, combination of the Hochwald grading system and Ki-67 PI achieved the highest CI (0.7946). Therefore, although all these systems predict RFS well in locoregional WD PanNETs, the Hochwald grading system achieves the highest predictive ability. Further predictive power can be achieved by combining the Hochwald grading system and Ki-67 PI.

Entities:  

Mesh:

Year:  2013        PMID: 23598967      PMCID: PMC3654011          DOI: 10.1097/PAS.0b013e31827fcc18

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

Review 1.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

2.  Endocrine pancreatic tumors: factors correlated with survival.

Authors:  P Tomassetti; D Campana; L Piscitelli; R Casadei; D Santini; F Nori; A M Morselli-Labate; R Pezzilli; R Corinaldesi
Journal:  Ann Oncol       Date:  2005-08-05       Impact factor: 32.976

3.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

4.  Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome.

Authors:  Martin Anlauf; Regina Schlenger; Aurel Perren; Juliane Bauersfeld; Christian A Koch; Henning Dralle; Andreas Raffel; Wolfram T Knoefel; Eberhard Weihe; Philippe Ruszniewski; Anne Couvelard; Paul Komminoth; Philipp U Heitz; Günter Klöppel
Journal:  Am J Surg Pathol       Date:  2006-05       Impact factor: 6.394

5.  Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables.

Authors:  G Pelosi; E Bresaola; G Bogina; F Pasini; S Rodella; P Castelli; C Iacono; G Serio; G Zamboni
Journal:  Hum Pathol       Date:  1996-11       Impact factor: 3.466

6.  Proliferative activity of neuroendocrine tumours of the gastroenteropancreatic endocrine system: DNA flow cytometric and immunohistological investigations.

Authors:  A von Herbay; B Sieg; G Schürmann; W J Hofmann; M Betzler; H F Otto
Journal:  Gut       Date:  1991-08       Impact factor: 23.059

7.  Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?

Authors:  Cristina R Ferrone; Laura H Tang; James Tomlinson; Mithat Gonen; Steven N Hochwald; Murray F Brennan; David S Klimstra; Peter J Allen
Journal:  J Clin Oncol       Date:  2007-12-10       Impact factor: 44.544

Review 8.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Authors:  Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

Review 9.  Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining.

Authors:  Mina Jamali; Runjan Chetty
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  23 in total

1.  Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.

Authors:  Laura H Tang; Brian R Untch; Diane L Reidy; Eileen O'Reilly; Deepti Dhall; Lily Jih; Olca Basturk; Peter J Allen; David S Klimstra
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

2.  Pancreatic Neuroendocrine Tumors: an Update.

Authors:  Alessandro Paniccia; Barish H Edil; Richard D Schulick
Journal:  Indian J Surg       Date:  2015-10-13       Impact factor: 0.656

3.  Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.

Authors:  Joo Young Kim; Sang Hwa Lee; Soyeon An; Sung Joo Kim; You-Na Sung; Ki-Byung Song; Dae Wook Hwang; Song Cheol Kim; Seung-Mo Hong
Journal:  Virchows Arch       Date:  2018-04-18       Impact factor: 4.064

4.  Biology and evolution of poorly differentiated neuroendocrine tumors.

Authors:  David S Rickman; Himisha Beltran; Francesca Demichelis; Mark A Rubin
Journal:  Nat Med       Date:  2017-06-06       Impact factor: 53.440

5.  Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience.

Authors:  Javier A Cienfuegos; Joseba Salguero; Jorge M Núñez-Córdoba; Miguel Ruiz-Canela; Alberto Benito; Sira Ocaña; Gabriel Zozaya; Pablo Martí-Cruchaga; Fernando Pardo; José Luis Hernández-Lizoáin; Fernando Rotellar
Journal:  Surg Endosc       Date:  2017-01-26       Impact factor: 4.584

6.  Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.

Authors:  Nitya Raj; Emily Valentino; Marinela Capanu; Laura H Tang; Olca Basturk; Brian R Untch; Peter J Allen; David S Klimstra; Diane Reidy-Lagunes
Journal:  Pancreas       Date:  2017-03       Impact factor: 3.327

Review 7.  Update on pancreatic neuroendocrine tumors.

Authors:  Logan R McKenna; Barish H Edil
Journal:  Gland Surg       Date:  2014-11

8.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

9.  A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.

Authors:  Laura H Tang; Olca Basturk; Jillian J Sue; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2016-09       Impact factor: 6.394

10.  A randomized clinical trial of nerve block to manage end-stage pancreatic cancerous pain.

Authors:  Ling Gao; Yi-jin Yang; Hai-yan Xu; Jin Zhou; Han Hong; Yun-liang Wang; De-chun Li
Journal:  Tumour Biol       Date:  2013-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.